Boston Scientific Receives FDA Approval for WATCHMAN™ Left Atrial Appendage Closure Device

March 13, 2015 10:58 PM

18 0

MARLBOROUGH, Mass., March 13, 2015 /PRNewswire/ -- Boston Scientific Corporation BSX, -1.66% has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN Left Atrial Appendage Closure Device. The WATCHMAN Device offers a new stroke risk reduction option for high-risk patients with non-valvular atrial fibrillation who are seeking an alternative to long-term warfarin therapy. The WATCHMAN Device will be made available to U.S. centers involved in our clinical studies and additional, specialized centers as physicians are trained on the implant procedure.

The WATCHMAN Device is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores, are deemed by their physicians to be suitable for...

Read more

To category page